Cell therapy for type 1 diabetes: Tracing historical progress and exploring emerging technologies.

Area of Science:

• Endocrinology and Metabolism
• Immunology
• Regenerative Medicine

Background:

• Type 1 diabetes is an autoimmune disease with ongoing challenges in glucose management and quality of life despite insulin therapies.
• Beta-cell replacement strategies, including islet transplantation, show promise but face limitations like donor scarcity and immunosuppression requirements.

Purpose of the Study:

• To review current advancements and future directions in cell-based therapies for type 1 diabetes.
• To highlight strategies addressing immune barriers and improving cell engraftment and function.

Main Methods:

• Review of current research in stem cell-derived therapies, islet encapsulation, xenotransplantation, and gene-editing for type 1 diabetes.
• Analysis of challenges in manufacturing, delivery, engraftment, and long-term efficacy of cell therapies.

Main Results:

• Stem cell-derived islets demonstrate potential for insulin independence and glycemic control.
• Encapsulation, iPSC-based therapies, and gene editing are being explored to mitigate immune rejection.
• Porcine islet xenotransplantation is under renewed investigation, facing regulatory and immunological challenges.

Conclusions:

• Cell therapies are transitioning towards clinical reality for type 1 diabetes, offering transformative potential.
• Scalable manufacturing, safe delivery, regulatory approval, and patient-centric approaches are crucial for successful implementation.
• Addressing immune barriers and ensuring long-term cell function are paramount for widespread therapeutic impact.